The metabolic syndrome: Diagnosis and treatment

Clinical Cornerstone

Volumn 6, Issue 3 SUPPL. 1, 2004, Pages

  Zieve, Franklin J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; HUMAN; HYPERLIPIDEMIA; LIFESTYLE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERLIPIDEMIAS; LIFE STYLE; METABOLIC SYNDROME X; PRACTICE GUIDELINES; RISK ASSESSMENT; RISK FACTORS;

EID: 17844400851     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(04)80093-0     Document Type: Article

References (52)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
2. Grundy S.M., Brewer Jr. H.B., Cleeman J.I., et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109 (2004) 433-438
3. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
4. Norhammar A., Tenors A., Nilsson G., et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: A prospective study. Lancet 359 (2002) 2140-2144
5. Malmberg K., and Ryden L. Myocardial infarction in patients with diabetes mellitus. Eur Heart J 9 (1988) 256-264
6. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO Consultation; Part 1: Diagnosis and classification of diabetes mellitus; 1999. Available at:. http://whglibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2.pdf Accessed December 12, 2003
7. Einhorn D., Reaven G.M., Cobin R.H., et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 9 (2003) 237-252
8. Hunt K.J., Resendez R.G., Williams K., et al. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to allcause and cardiovascular mortality in the San Antonio Heart Study. Circulation 110 (2004) 1251-1257
9. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
10. Malik S., Wong N.D., Franklin S.S., et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110 (2004) 1245-1250
11. Girman C.J., Rhodes T., Mercuri M., et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 93 (2004) 136-141
12. Wilson PW D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
13. Grundy S.M., Hansen B., Smith S.C., et al. Clinical management of metabolic syndrome: Report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 109 (2004) 551-556
14. National Institutes of Health. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults-the evidence report. Obes Res. 2 Suppl 6 (1998) 51S-209S
15. Thompson P.D., Buchner D., Pina I.L., et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: A statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 107 (2003) 3109-3116
16. Krauss R.M., Eckel R.H., Howard B., et al. AHA Dietary Guidelines: Revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 102 (2000) 2284-2299
17. Haddock C.K., Poston W.S., Dill P.L., et al. Pharmacotherapy for obesity: A quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 26 (2002) 262-273
18. Capella J.F., and Capella R.F. The weight reduction operation of choice: Vertical banded gastroplasty or gastric bypass?. Am J Surg 171 (1996) 74-79
19. Knowler W.C., Barrett-Canner E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
20. Kraus W.E., Houmard J.A., Duscha B.D., et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 347 (2002) 1483-1492
21. Heart Protection Study Collaborative Group. MRC/ BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360 (2002) 7-22
22. Grundy S.M., Cleeman J.I., Merz N.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 110 (2004) 227-239
23. Pyorala K., Ballantyne C.M., Gumbiner B., et al. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: Subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 27 (2004) 1735-1740
24. Haffner S.M., Alexander C.M., Cook T.J., et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: Subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 159 (1999) 2661-2667
25. Davidson M.H., McGarry T., Bettis R., et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. JAm Coll Cardiol 40 (2002) 2125-2134
26. Cannon C.P., Braunwald E., McCabe C.H., et al., Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
27. Austin M.A., King M.C., Vranizan K.M., and Krauss R.M. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 82 (1990) 495-506
28. Canner P.L., Berge K.G., Wenger N.K., et al. Fifteen year mortality in Coronary Drug Project patients: Longterm benefit with niacin. J Am Coll Cardiol 8 (1986) 1245-1255
29. Frick H.M., Elo O., Haapa K., et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treat ment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317 (1987) 1237-1245
30. Rubins H.B., Robins S.J., Collins D., et al., Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341 (1999) 410-418
31. Gruppo Italiano per to Studio della Sopravvivenza nell'Infarto miocardico. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI Prevenzione trial. Lancet 354 (1999) 447-455
32. Carlson L.A., and Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofi brate and nicotinic acid. Acta Med Scand 223 (1988) 405-418
33. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001) 1583-1592
34. Krasuski R.A., Maranian A.M., Whitney E.J., et al. Aggressive treatment aimed at raising high-density lipoprotein cholesterol in stable patients with angio graphically evident coronary disease prevents stenosis progression and reduces cardiovascular events. J Am Coll Cardiol 41 Suppl 1 (2003) 315
35. Bays H.E., Dujovne C.A., McGovern M.E., et al. Advicor versus other cholesterol-modulating agents trial evaluation. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the Advicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol 91 (2003) 667-672
36. Jacobson T.A. Combination lipid-lowering therapy with statins: Safety issues in the postcerivastatin era. Expert Opin Drug Saf 2 (2003) 269-286
37. Prueksaritanont T., Tang C., Qui Y., et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 30 (2002) 1280-1287
38. Vega G.L., Ma P.T., Cater N.B., et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol 91 (2003) 956-960
39. Delarue J., LeFoll C., Corporeau C., et al. N-3 long chain polyunsaturated fatty acids: A nutritional tool to prevent insulin resistance associated to type 2 diabetes and obesity?. Reprod Nutr Dev 44 (2004) 289-299
40. Chobanian A.V., Bakris G.L., Black H.R., et al., The National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 289 (2003) 2560-2572
41. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 27 Suppl 1 (2004) S15-S35
42. Yusuf S., Gerstein H., Hoogwerf B., et al. Ramipril and the development of diabetes. JAMA 286 (2001) 1882-1885
43. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: The DREAM trial. Diabetologia 21 (2004) [Epub ahead of print]
44. Prisant L.M. Preventing type II diabetes mellitus. J Clin Pharmacol 44 (2004) 406-413
45. Pearson T.A., Blair S.N., Daniels S.R., et al., American Heart Association Science Advisory and Coordinating Committee. AHA Guidelines for primary prevention of cardiovascular disease and stroke: 2002 Update: Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 106 (2002) 388-391
46. Tuomilehto J., Lindstrom J., Eriksson J.G., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344 (2001) 1343-1350
47. Chiasson J.L., Josse R.G., Gomis R., et al. Acarbose for prevention of type 2 diabetes mellitus: The STOPNIDDM randomized trial. Lancet 359 (2002) 2072-2077
48. Buchanan T.A., Xiang A.H., Peters R.K., et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51 (2002) 2796-2803
49. Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care 26 (2003) 1306-1308
50. Chiasson J.L., Josse R.G., Gomis R., et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial. JAMA 290 (2003) 486-494
51. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [published correction appears in Lancet. 1998;352:1557]. Lancet 352 (1998) 854-865
52. Ridker P.M., and JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: Rationale and design of the JUPITER trial. Circulation 108 (2003) 2292-2297